DESCRIPTIVE ANALYSIS OF REAL-WORLD MEDICATION PATTERNS AND ONE-YEAR OUTCOMES OF ACUTE CORONARY SYNDROME PATIENTS WITH METABOLIC SYNDROME IN A TERTIARY CARE HOSPITAL

The prognostic association between metabolic syndrome (MS) and long-term survival of patients with acute coronary syndrome (ACS) in the era of intervention revascularization and high-precision medication had not yet been fully established. The latest ACS guidelines recommend the combined drug regimen, comprising acetylsalicylic acid (ASA), P2Y(12) (purinergic receptor P2Y(12)) inhibitors, angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), beta-blocker, and statin, to reduce recurrent ischemic cardiovascular events and mortality. The present study examined the prescription patterns of ACS long term-therapies among MS patients and analysed the association between guidelines medication and major adverse events. 49.44% of ACS patients included in this study received all five guidelinere-commended medications. Deaths occurred predominantly in MS patients receiving less medication, meanwhile major ischemic and bleeding events increased statistically with the number of drug combinations.